![1]()
News
Predicting patient risk of medication-related harm
November 18, 2020
Clinicians can calculate the risk of a patient suffering medication-related harm post-discharge.
News
Dapagliflozin trial in CKD halted because of high efficacy
March 30, 2020
An independent data monitoring committee recommended stopping the trial.
News
New ASAM guideline released amid COVID-19 concerns
March 20, 2020
During the COVID-19 pandemic, “it is especially important” for clinicians to ensure that individuals with OUD continue to receive evidence-based care, said Dr. Paul H. Earley.
News
Pathways to new therapeutic agents for human coronaviruses
February 13, 2020
Researchers have been identifying old and new therapeutics to target metabolic pathways and modes of infection for human coronaviruses.
![1]()
News
What 2019’s top five CAD trials tell us
January 29, 2020
SNOWMASS, COLO. – Triple therapy as a triple threat – a three-pronged threat to patient safety, Dr. Malcolm R. Bell says.
![1]()
News
Cardiac biomarkers refine antihypertensive drug initiation decisions
January 22, 2020
PHILADELPHIA – Analysis showcases a better way to select patients for intensive BP lowering.
![1]()
News
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
December 16, 2019
LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib.
![1]()
News
New heart failure trial data presage guideline revisions
December 9, 2019
PHILADELPHIA – Recent trial findings for sacubitril/valsartan and dapagliflozin in heart failure patients provide a blueprint for guideline changes.
![1]()
News
Aspirin plus a DOAC may do more harm than good in some
December 8, 2019
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication increased bleeding risks in a large cohort.
![1]()
News
DAPA-HF: Dapagliflozin benefits regardless of age, HF severity
November 25, 2019
PHILADELPHIA – The SGLT2 inhibitor had similar efficacy in the elderly, and across the spectrum of baseline symptom status.
